The resale of a massive number of shares (12.75B ordinary shares) into a very small market cap ($5M) creates significant near-term downside risk due to dilution and selling pressure. Traders should monitor for immediate selling by warrant holders and assess whether exercises are cashless (worse for equity value) or for cash (provides minimal capital).
Price Chart
Executive Summary
Akari Therapeutics' S-1 registration has become effective, allowing the resale of up to 6.375 million American Depositary Shares (ADSs) representing 12.75 billion ordinary shares by selling shareholders. The company will not receive proceeds from the resale, though it may receive up to $6.25 million if warrants are exercised on a cash basis.
Key Facts
- S-1 registration effective as of April 15, 2026, enabling resale of 6,375,000 ADSs (representing 12.75 billion ordinary shares).
- Shares being resold consist of warrants issued in a private placement: 3.125 million ADSs from Series E warrants, 3.125 million ADSs from Series F warrants, and 125,000 ADSs from placement agent warrants.
- Company will not receive proceeds from the resale of ADSs by selling shareholders.
- Company may receive up to $6,250,000 if warrants are exercised on a cash basis (non-cashless), though this is not guaranteed.
- Market cap is only $5 million, indicating the potential offering size could represent massive dilution.
Financial Impact
Potential issuance of 12.75 billion ordinary shares if all warrants are exercised; company may receive up to $6,250,000 in proceeds if exercised cash basis.
Risk Factors
- Extreme share dilution given the company's tiny market cap
- Selling pressure from resale of a large number of shares into a thin market
- Uncertainty around whether warrant exercises will be cashless, which would maximize dilution
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| EFFECT Filing (Primary) | 9999999995-26-001192 |
| Document: 9999999995-26-001192-index.html | 9999999995-26-001192 |
| Document: 9999999995-26-001192.txt | 9999999995-26-001192 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 1, 2026 25d ago | DEF 14A | $8.72 | awaiting T+60 | — | $8.00 (−8.26%) |
Oct 1, 2026 25d ago | 8-K | $8.72 | awaiting T+60 | — | $8.00 (−8.26%) |
Aug 13, 2026 10w ago | 8-K | $7.54 | awaiting T+60 | — | $8.00 (+6.10%) |
Jul 14, 2026 15w ago | EFFECT | $13.42 $8.63 | ▲ +35.73% | ▲ +39.11% | $8.00 (+40.39%) |
Jul 8, 2026 15w ago | EFFECT | $14.21 $8.84 | ▼ −37.79% | ▼ −40.28% | $8.00 (−43.70%) |
Jul 2, 2026 16w ago | S-3 | $10.41 $9.81 | ▲ +5.76% | ▲ +9.33% | $8.00 (+23.15%) |
Jun 29, 2026 17w ago | Press Release | $9.69 $10.05 | ▲ +3.72% | ▼ −0.67% | $8.00 (−17.44%) |
Jun 26, 2026 17w ago | 8-K | $9.69 $10.05 | ▲ +3.72% | ▼ −0.67% | $8.00 (−17.44%) |
May 28, 2026 21w ago | Press Release | $22.05 $7.85 | ▼ −64.40% | ▼ −66.13% | $8.00 (−63.72%) |
May 22, 2026 22w ago | 8-K | $17.81 $7.90 | ▲ +55.64% | ▲ +58.37% | $8.00 (+55.08%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers